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C→T Transition Mutations Are  
Not Solely UVB-Signature 
Mutations, Because They Are  
Also Generated by UVA
Thomas M. Rünger1
In this issue, Ikehata et al. confirm data from cell culture models by showing 
that the C→T transition mutation is also the most common UVA-generated 
mutation in vivo. This indicates that DNA photoproducts are the most impor-
tant premutagenic lesions not only in UVB mutagenesis, but also in UVA muta-
genesis. C→T transitions cannot therefore be considered solely UVB-signature 
mutations. In addition, there is no consistent evidence for a separate UVA-
generated UVA signature mutation. We hypothesize that weaker anti-muta-
genic cellular responses to UVA, as compared to UVB, may result in higher 
rates of mutation formation for UVA-induced dimers.
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Ultraviolet (UV) light contains a spec-
trum of different wavelengths with dif-
ferent photophysical, photochemical, 
and photobiological properties. The sub-
division of solar UV light reaching the 
earth’s surface into UVB (280–315 nm) 
and UVA (315–400 nm; often further 
subdivided into UVA2, 315–340 nm, 
and UVA1, 340–400 nm) is rather arbi-
trary, because their properties change 
only gradually with increasing wave-
lengths from the UVB to the UVA range. 
Nevertheless, the relative contributions 
of different wavelengths (in a simplified 
way, UVB versus UVA) to photoderma-
tologic end points such as photoaging 
and photocarcinogenesis, as well as the 
mechanisms by which UVB and UVA 
exert such effects, remain a matter of 
debate. The “photocarcinogenesis chain 
of events” involves formation of DNA 
damage following UV exposure, forma-
tion of mutations at sites of UV-induced 
DNA damage, and, finally, malignant 
transformation after the accumulation of 
a sufficient number of mutations in criti-
cal genes (Rünger, 2007).
The question of which types of 
DNA damage are formed with UVB 
and UVA exposure has been studied 
extensively, but information about the 
mutagenic consequences of the vari-
ous types of UVB- and UVA-induced 
DNA lesions is more limited. The 
observation that the action spectrum 
for the formation of DNA photo-
products (pyrimidine dimers of the 
cyclobutane pyrimidine dimer type or 
the 6,4-photoproduct type) runs par-
allel to the action spectrum for mouse 
squamous cell carcinoma in the UVB 
and UVA2 range (de Gruijl et al., 1993) 
has been interpreted as supporting a 
major role for DNA photoproducts in 
skin carcinogenesis. C→T transition 
mutations are typically formed at 
C-containing DNA photoproducts. The 
observation that this type of mutation 
is commonly found in UV-induced 
skin cancers (squamous cell carcino-
mas, basal cell carcinomas, and mela-
nomas) but rarely in non-UV-induced 
internal cancers further supports a 
major role of DNA photoproducts in 
photocarcinogenesis. C→T transition 
mutations have therefore been termed 
UV-signature or UV-fingerprint muta-
tions (Wikondahl and Brash, 1999).
The observation that the action spec-
trum for skin cancer formation exhibits 
a second peak with increasing wave-
lengths further into the UVA1 range, 
whereas DNA photoproduct formation 
further declines (de Gruijl et al., 1993), 
and a second observation of an increase 
in mutation rate per photoproduct with 
increasing wavelengths (Enninga et al., 
1986) have been interpreted in the past 
as supporting a role of a non-DNA-
photoproduct DNA damage in UVA 
mutagenesis. Oxidative DNA damage, 
which occurs more efficiently with UVA 
than with UVB, has often been suggest-
ed as the premutagenic lesion in UVA 
mutagenesis. This concept has been 
questioned, however, because only a 
small fraction of UVA-induced muta-
tions observed in cell culture models 
were typical of oxidative DNA dam-
age (reviewed by Rünger and Kappes, 
2008). With cultured primary human 
fibroblasts, the mutations induced by 
UVB and UVA were actually quite 
similar (Kappes et al., 2006)—a pre-
dominance of C→T transitions for both 
UVA and UVB, sharing of hotspots 
within runs of pyrimidines, and a pre-
dilection of these mutations for the 
nontranscribed strand all support the 
concept of DNA photo products as the 
major premutagenic lesion not only for 
UVB but also for UVA.
To reconcile these findings with the 
earlier observations, we hypothesize 
that it is not a different or additional 
type of DNA damage that explains the 
increased mutation and tumor forma-
tion per photoproduct with UVA but 
weaker antimutagenic cellular DNA 
damage responses that ultimately result 
in higher rates of mutation formation 
at DNA photoproducts when gener-
ated with UVA. We have been able to 
demonstrate such weaker responses 
following exposure to UVA by com-
paring equimutagenic doses of UVA 
and UVB (Kappes et al., 2006; Rünger 
and Kappes, 2008). Furthermore, UVA 
may even inhibit protective responses 
(Ibuki et al., 2007; Rünger, 2007).
Using UVA-irradiated transgenic 
mice harboring λ-phage lacZ mutational 
reporter genes, Ikehata et al. (2008, this 
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issue) contribute important informa-
tion to the ongoing UVA-mutagenesis 
discussion as they describe the types 
of mutations generated by UVA in vivo. 
Previously, such data were available 
only from cell culture models. In addi-
tion, their in vivo model allows muta-
tion formation to be studied separately 
in epidermis and dermis. Their work 
confirms that oxidative DNA damage, 
although it occurs with UVA irradia-
tion, is not a major contributor to UVA 
mutagenesis, because the types of 
mutations commonly generated by oxi-
dative DNA damage—e.g., G→T and 
T→G transversions with 8-oxo-7,8-di-
hydroguanine—constitute only a small 
fraction (8% of all observed mutations) 
of UVA-induced mutations.
Ikehata et al. also confirm that 
DNA photoproducts are indeed the 
most common premutagenic DNA 
lesions in UVA mutagenesis, because 
the majority of UVA-induced muta-
tions (65% of all observed mutations) 
were C→T transitions, albeit not 
quite as common as with UVB (85%). 
Further analysis of these C→T transi-
tions revealed that a large majority 
were located at 5´-TCG-3´ sequences, 
whereas only a small fraction of UVB-
induced C→T transitions were located 
at such sequences. From that observa-
tion, the authors conclude that UVA 
may generate DNA photoproducts 
through a different mechanism, not (or 
not only) via direct excitation of the 
DNA molecule as with UVB photons, 
but via a photosensitization-mediated 
triplet energy transfer mechanism. On 
the basis of studies with Chinese ham-
ster ovary cells, such a mechanism has 
already been suggested (Douki et al., 
2003, and others).
The differences between the UVA- 
and the UVB-induced mutations stand 
in contrast to our observations with 
primary human fibroblasts (Kappes 
et al., 2006). Many possible factors 
could account for such different out-
comes, including the light sources 
(monochromatic UVA1 laser versus 
a broad-spectrum UVA1 source), 
doses employed (Ikehata et al. (2008) 
used very high doses that are usu-
ally not reached during a day of sun 
exposure), mutagenesis targets (unlike 
the hprt gene we used for the muta-
genesis assays with human fibroblasts, 
the lacZ transgenes used by Ikehata et 
al. (2008) are not expressed and are 
therefore not subjected to the faster 
transcription-coupled nucleotide exci-
sion repair pathway), assay designs 
(the in vivo approach of Ikehata et al. 
(2008) avoids many of the artificial 
conditions inherent in cell culture 
models), and species (mouse versus 
human). This last difference appears to 
be of particular importance, because 
nucleotide excision repair of DNA 
photoproducts—which plays a major 
role in preventing mutation formation 
of DNA photoproducts—is much less 
efficient in (nocturnal) rodents than in 
(diurnal) humans (Hanawalt, 2001).
The in vivo work of Ikehata et al. 
(2008) confirms that the C→T tran-
sition is not solely a UVB-signature 
mutation, because it is also generated 
by UVA. C→T transitions are formed 
at sites of C-containing pyrimidine 
dimers, which are generated by both 
UVA and UVB. Furthermore, there is 
no confirmed evidence for a separate 
UVA-signature mutation (Rünger and 
Kappes, 2008).
Oxidative DNA damage does not 
appear to play an important role in 
either UVA or UVB mutagenesis. 
Antioxidants, despite already being 
widely used in sunscreen products, 
may therefore not affect mutation 
form ation with solar UV radiation.
We still do not know all the 
determinants that act on the 
“photocarcinogenesis chain of events.” 
Aspects that have not been sufficiently 
addressed are the influence of repeated 
UVA/UVB exposure, the influence of 
cell-specific differences and of cell–
cell interactions within skin, and how 
the different wavelengths interact in 
the intricate interplay of promutagenic/
procarcinogenic influences and 
ant i  muta  genic /ant icarc inogenic 
cellular respon ses. If our hypothesis—
that a UVA-induced pyrimidine dimer 
is more mutagenic than a UVB-induced 
pyrimidine dimer because of a lack of 
an efficient antimutagenic response to 
UVA—is correct, pure UVA (without 
concurrent UVB) may be more muta-
genic than UVA from a mixed UVA 
+ UVB source (such as natural sun-
light), because UVB induces a protec-
tive response that also protects against 
mutation formation from UVA-induced 
DNA photoproducts. Exposures to 
such pure UVA do occur in the mod-
ern world, e.g., with (i) sun exposure 
through window glass, (ii) the use of 
non-broad-spectrum sunscreen formu-
lations that filter UVB effectively but do 
not filter (or to a much lesser degree) 
UVA, (iii) some UVA tanning devices, 
and (iv) UVA1 phototherapy. Because 
early humans were not exposed to pure 
UVA, evolution may not have devel-
oped adequate protection against it. 
Obviously, more work is in order.
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epidermolysis Bullosa:  
Prospects for Cell-Based Therapies
Jouni Uitto1
Heritable forms of epidermolysis bullosa (eB) are characterized by chronic, lifelong 
blistering and erosions due to mutations in 10 distinct genes expressed at the cuta-
neous basement membrane zone. No specific treatment for this group of intract able 
diseases is currently available. recent progress in molecular therapies has indicated 
that cell-based approaches may potentially offer amelioration—and perhaps even 
cure—for afflicted individuals. In this issue, Wong et al. (2008) demonstrate the 
feasibility of direct intradermal injection of allo geneic fibroblasts to the lesional skin 
of patients with recessive dystrophic eB, with improvement in skin fragility.
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Epidermolysis bullosa (EB) is a clinically 
and genetically heterogeneous group of 
diseases presenting with skin fragility as 
the unifying diagnostic hallmark (Fine 
et al., 2008). Histopathology of the cuta-
neous blisters reveals separation of the 
epidermis from the underlying dermis 
at the level of the cutaneous basement 
membrane zone. Tremendous progress 
in molecular genetics of this group of 
disorders over the past two decades has 
revealed that the blistering tendency is 
due to mutations in 10 distinct genes 
expressed at the dermal–epidermal junc-
tion. The precise level of the expression 
of the mutated genes within the cutane-
ous basement membrane zone, the types 
and combinations of the mutations, and 
their consequences at mRNA and protein 
levels, when superimposed on the indi-
vidual’s genetic background and exposure 
to environmental trauma, all explain the 
spectrum of severity in affected individuals 
and form the basis of a molecular-based 
classification (Uitto and Richard, 2005).
Among the most severe forms of EB 
are the dystrophic subtypes, particularly 
the recessive Hallopeau–Siemens vari-
ant, (HS-RDEB). The dystrophic forms of 
EB are due to mutations in the type VII 
collagen gene, COL7A1, and HS-RDEB 
is frequently caused by premature ter-
mination codon-causing mutations that 
result in functional null alleles (Varki et 
al., 2007). As a result, blistering and ero-
sions develop upon exposure to relative-
ly minor trauma, leading to subsequent 
healing with extensive fibrosis. No spe-
cific treatment, short of protection from 
trauma, is currently available for patients 
with any form of EB.
The prospects of gene therapy for EB 
have been contemplated over the years, 
and, in fact, this disorder is an excellent 
candidate disease for molecular therapy 
approaches for several reasons (Uitto 
and Pulkkinen, 2000). First, skin is read-
ily accessible for delivery of the trans-
gene, either in the form of expression 
plasmids or packaged in cells delivered 
directly to the skin. The consequences 
of the gene delivery can be observed 
visually, and potential amelioration of 
the skin fragility can be easily measured 
by mechanical means. Furthermore, the 
treated areas of skin can be removed 
if evidence of adverse effects, such as 
cancer development, is noted. A num-
ber of preclinical model systems—such 
as transplantation of EB patients’ skin 
onto immunocompromised mice as a 
xenograft or injection of genetically cor-
rected cells, such as fibroblasts, to RDEB 
mice—have indicated the feasibility of 
gene therapy approaches for EB (Ortiz-
Urda et al., 2003; Goto et al., 2006; 
Woodley et al., 2007; Fritsch et al., 
2008). As a direct clinical application, 
correction of skin fragility in a patient 
with junctional EB (JEB) was recently 
demonstrated (Mavilio et al., 2006). In 
this case, epidermal stem cells from the 
skin of a patient with mutations in the 
LAMB3 gene encoding the β3 subunit 
of laminin 332 were isolated and then 
transduced in culture with a retroviral 
LAMB3 expression vector. The cells were 
then grown into epidermal sheets that 
were grafted onto surgically prepared 
areas of the patient’s skin. Follow-up for 
more than 1 year has demonstrated sus-
tained synthesis and proper assembly of 
laminin 332 in the grafted area, togeth-
er with the development of a firmly 
adherent epidermis. There has been no 
evidence of blistering, inflammation, or 
immune response in the corrected area. 
These data suggested, therefore, that ex 
vivo gene therapy may be feasible for 
JEB and that this approach can lead to 
fully functional correction of the disease 
in the skin. A general concern associated 
with the use of retroviral vectors, howev-
er, is the potential for insertional carcino-
genesis due to random integration of the 
transgene to the genome (Featherstone 
and Uitto, 2007). Furthermore, only rel-
atively small areas can be treated at any 
given time, and the procedure involves 
considerable invasive preparation of the 
recipient skin for grafting. For these rea-
sons, complementary approaches uti-
lizing protein- and cell-based therapies 
have recently been contemplated.
